Printer Friendly

SOMATIX ANNOUNCES APPOINTMENT OF ONCOLOGIST

 SOMATIX ANNOUNCES APPOINTMENT OF ONCOLOGIST
 ALAMEDA, Calif., July 17 /PRNewswire/ -- Somatix Therapy Corp.


(NASDAQ: SOMA) today announced that Albert H. Owens, Jr., M.D. has joined the company as director of oncology and infectious diseases. In this new position, Owens will be responsible for the company's cancer program, and serve as the clinical liaison for human trials.
 Owens, a professor at The Johns Hopkins University School of Medicine, was most recently director of the oncology center at that institution, and previously, president of The Johns Hopkins Hospital. He has participated in numerous cancer research committees including a term as the president of the Association of American Cancer Institutes and chairman of the National Coalition for Cancer Research. He is a trustee of the Johns Hopkins Hospital and a member of the boards of the Baltimore Life Insurance Co. and Optimedx, a privately held company.
 "Dr. Owens brings a wealth of cancer research experience to Somatix," stated David W. Carter, the company's chief executive officer. "He is a highly respected clinician and administrator. Owens will be instrumental in successfully taking the company's cancer program from the research laboratory into the clinic."
 Somatix Therapy Corp. is a scientific leader in the emerging field of gene therapy. The company is focused on the genetic modification of selected human cells to enable the production and delivery of therapeutic substances within the patient's body. Somatix believes that gene therapy, which requires gene transfer technology, will provide a safe and effective means of delivering many therapeutic substances. Somatix has gene therapy programs in cancer, central nervous system diseases and hemophilia.
 -0- 7/17/92
 /CONTACT: Julie Wood of Somatix Therapy, 510-748-3082/
 (SOMA) CO: Somatix Therapy Corp. ST: California IN: MTC SU: PER


JL -- SF003 -- 0266 07/17/92 12:55 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 17, 1992
Words:295
Previous Article:NEWBRIDGE-SUPPLIED TELECOM DENMARK FRAME RELAY FIELD TRIAL NETWORK GOES INTO SERVICE
Next Article:FIRST OF MICHIGAN CAPITAL CORPORATION REPORTS INCREASED EARNINGS FOR THIRD QUARTER
Topics:


Related Articles
SOMATIX NAMES EXECUTIVE VICE PRESIDENT OF COMMERCIAL DEVELOPMENT
SOMATIX NAMES SOFRONIEW TO HEAD NEURAL PROGRAM
SOMATIX RECEIVES EXCLUSIVE WORLDWIDE LICENSE ON CANCER GENE THERAPY PATENT APPLICATION
SOMATIX ANNOUNCES APPOINTMENT OF RESEARCH SURGEON
SOMATIX APPOINTS BERNS EXECUTIVE VICE PRESIDENT OF R&D
SOMATIX REPORTS FIRST QUARTER RESULTS
SOMATIX REPORTS SECOND QUARTER RESULTS
TARGETED GENETICS APPOINTS DIRECTOR OF DEVELOPMENT
Thios Pharmaceuticals Appoints Bruce A. Hironaka Chief Executive Officer.
ARCA Discovery, Inc. Names Dr. Ann Lenich Hards Executive Vice President Regulatory Affairs.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters